Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1771 to 1785 of 1863 results for do not dos

  1. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

  2. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

  3. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.

  4. Pegzilarginase for treating arginase-1 deficiency in people 2 years and over (HST35)

    Evidence-based recommendations on pegzilarginase (Loargys) for treating arginase-1 deficiency in people 2 years and over.

  5. LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)

    NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments

  6. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (HTG316)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.

  7. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  8. Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.

  9. Personal, social, health and economic education focusing on sex and relationships and alcohol education

    Discontinued Reference number: GID-PHG0

  10. Digital platforms recommended to help people manage their asthma

    People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.

  11. Harnessing digital innovation for children's mental health

    Learn how NICE healthtech guidance helped East London NHS Foundation Trust tackle rising demand for children's mental health services.

  12. Changes to NICE's cost-effectiveness thresholds confirmed

    The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.

  13. Seven digital platforms supporting at home cardiac rehab given conditional recommendations

    People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.

  14. Fertility clinics must end unproven treatments that don't help couples have babies

    Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.

  15. Accelerating innovation: How NICE is opening pathways to digital health technologies for the NHS

    Following her appearance at this year’s HETT Show, programme director Sarah Byron tells us why the government’s 10 Year Plan is a game changer for healthtech and how we’re driving the changes at NICE.